

Amicus Therapeutics UK Operations Limited Transparency Reporting Methodological Note

Introduction

Amicus is proud to work with healthcare professionals for the benefit of patients. These interactions allow Amicus to gather advice and insights on a wide range of topics including medicines development, patient treatment pathways, health economics and clinical best practice. We believe that transparency is vital to strengthen the foundations for future collaboration.

This methodological note is intended to help readers understand how Transfers of Value (“**ToVs**”) from Amicus to Healthcare Professionals (**HCPs**), Healthcare Organisations (“**HCOs**”) and Other Relevant Decision Makers (“**ORDMs**”) (collectively referred to as “**Recipients**”) within the countries of the United Kingdom, have been collated and reported.

Standard Definition of Recipients of Transfer of Value reported by Amicus

- **Healthcare Organisation (“HCO”)** - either a healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in the United Kingdom or an organisation through which one or more health professionals or other relevant decision makers provide services.
- **Healthcare Professional (“HCP”)** - Any member of the medical, dental, pharmacy or nursing profession and any other person who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine. In relation to the annual disclosure of Transfer of Value, the term also includes any employee of Amicus whose primary occupation is that of a practising healthcare professional.
- **Other Relevant Decision Maker (“ORDM”)** - particularly includes someone with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who is not a health professional.

Transfers of Value (“TOVs”)

ToVs include a direct or indirect transfer of value, whether in cash, in-kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines.

TOVs paid to a company owned by a healthcare professional are disclosed against the name of the individual HCP. Transfers of value paid to organisations not owned by an individual HCP are disclosed against the name of the organisation, unless the organisation has directed Amicus to disclose it against the name of the relevant healthcare professional.

Where service fees are paid to an HCO but there is an expense attributable to an individual, the ToV is reported for the individual:

- **Direct Transfers of Value** - Direct ToVs whether in cash, in kind or otherwise, are those paid by an Amicus affiliate to a Recipient.

- **Indirect Transfers of Value** - Indirect ToVs are those made on behalf of an Amicus affiliate for the benefit of a Recipient, or those made through a third party and where the Amicus affiliate knows or can identify the Recipient that will benefit from the ToV.

Transfer of Value Dates

ToV dates stated in the disclosure report are the dates of the payment to the Recipient. Any payment made to a Recipient which falls within the reporting period will be disclosed.

Where ToVs are related to multi-year contracts, only the ToVs made in the reporting period are included.

Where a ToV is a benefit in kind, for example travel or accommodation, the payment date is taken as the event date.

Categories of Transfers of Value

ToVs may arise from the following broad types of activity (there are others):

- **Contribution to costs related to events** - Support providing or covering travel, accommodation and/or registration fees to support the attendance of an individual HCP, ORDM or patient organisation representative to an event organised or created by Amicus and/or a third party is included in the report.
- **Fees for services and consultancy** – Amicus engages Recipients for services when there is a genuine and legitimate business need and there is alignment with the expertise of the HCP. Recipients are paid for these services at a fair market value rate. Related expenses may also be included as part of the contractual services in order for the Recipient to execute the assignment related to the contract. The ToV reported is the actual amount paid for payment services, and the related expenses.
- **Research and Development** - Transfers of Value to HCPs or HCOs related to the planning or conduct of non-clinical studies, clinical trials or non-interventions studies that are prospective in nature and that involve the collection of patient data from or on behalf of individuals, or groups of, HCPs specifically for the study. The disclosure includes both Amicus and CRO managed studies, investigator Initiated studies and academic research in the R&D section of the report.
- **Market Research** - ToVs might be made to HCPs in return for answering questions about Amicus products and / or a therapeutic area. Amicus generally participates in “double blinded” market research where it does not know the identities of the participants, and has therefore not reported any ToVs for these market research activities.
- **Donations and grants** – Donations and grants to HCOs, in cash or in kind that are freely given for the purpose of supporting healthcare, scientific research or education are included in the report. Donations to HCOs that are funded by employee contributions are not included in the report. Gift matching contributions from Amicus are reported.
- **HCO Sponsorship** – Sponsorship, including contributions to costs related to events/meetings paid to HCOs directly or indirectly via third parties organising events on behalf of an HCO are included in the report. This may include support of HCPs not known to Amicus via the HCO by

way of registration fees, accommodation and travel. Subsistence provided to HCPs or ORDMs where they are supported to attend events/meetings are not reported.

- **Collaborative Working** – includes Joint Working, with HCOs and may also include patient organisations, in activities which either enhance patient care or are for the benefit of patients and/or benefit the HCO and as a minimum maintains patient care, where there is a shared commitment to successful delivery.

Cross-Border Spend

Amicus operates in many countries and therefore may contract HCPs from different countries to perform services in other markets. Some ToVs to Recipients are made by an Amicus affiliate that is not the home country of that Recipient. Home country refers to the country where the recipient has their primary place of practice or registration. Disclosures of these ToVs will be made in the Recipient's home country. Similarly, ToVs to HCOs will be disclosed in their home country, regardless of which Amicus affiliate (directly or indirectly) made the payment, etc.

Currency

All TOVs are disclosed in local currency. If payments were made in a currency other than that of the home country of the HCP/HCO/ORDM, these are converted based on the conversion rate on the date of payment. Therefore, the total amounts disclosed could vary slightly from the exact amount in the local currency.

Treatment of Tax

The ABPI permits companies to choose whether to report ToVs inclusive or exclusive of taxes. Amicus has chosen to report exclusive of taxes.

Legal Basis for Disclosure

ToVs are publicly disclosed on an individually named basis. Amicus relies on legitimate interest as the legal basis under data privacy laws, for disclosure of this information. When Amicus receives an opt out request from an HCP, Amicus requests that the HCP explain the reason for the request. All requests are assessed on a case by case basis using the balancing test set out in the ABPI Legitimate Interest toolkit and in line with data privacy law.

Amicus does not permit partial individual disclosure, i.e. either all ToVs made to a Recipient in the reporting period are disclosed individually, or they are all disclosed in aggregate.

Dispute Management

When possible, before any publications are made, Amicus will provide HCPs with the opportunity to check the information that is held to ensure that it is accurate and complete. If Amicus is unable to contact an HCP about the annual TOVs paid to them, the HCP will have an opportunity to object to disclosure when contacted by the ABPI prior to the disclosure publication.

Requests or disputes related to the disclosure report, these can be reported to:
Disclosure-ABPI@amicusrx.com.

Document Retention

Amicus' document retention period is five years following the disclosure year, in line with ABPI's retention period.

Approved: March 2025